We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ILA market cap is 19.91M. The company's latest EPS is AUD -0.0252 and P/E is -6.75.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 0 | 0 | 11k | 1.26M |
| Operating Income | -1,000 | -2.14M | -2.81M | -2.9M | -2.86M |
| Net Income | -1,000 | -2.13M | -2.61M | -2.83M | -2.86M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 0 | 6.64M | 4.9M | 2.05M | 2.56M |
| Total Liabilities | 1,000 | 237k | 581k | 264k | 1.05M |
| Total Equity | -1,000 | 6.4M | 4.32M | 1.79M | 1.52M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | N/A | -938k | -1.88M | -2.7M | -3.17M |
| Investing | N/A | 77k | N/A | N/A | N/A |
| Financing | N/A | 7.3M | N/A | -180k | 2.79M |
| Market Cap | 19.91M |
| Price to Earnings Ratio | -6.75 |
| Price to Sales Ratio | 15.32 |
| Price to Cash Ratio | 11.64 |
| Price to Book Ratio | 12.74 |
| Dividend Yield | - |
| Shares Outstanding | 113.8M |
| Average Volume (1 week) | 695.89k |
| Average Volume (1 Month) | 903.51k |
| 52 Week Change | 157.35% |
| 52 Week High | 0.195 |
| 52 Week Low | 0.05 |
| Spread (Intraday) | 0.02 (8.33%) |
| Company Name | Illawarra Series 2006 1 Rmbs Trust |
| Address |
c/- bio101 financial advisory pty ltd melbourne, victoria 3124 |
| Website | https://www.islandpharmaceuticals.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
